Azar Says J&J (JNJ) Vaccine Trial Setback Shouldn't Alter Timeline - Bloomberg
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St set to snap three-day losing streak as stocks reclaim some shine
- Oil rises 1%, as US-Iran strikes risk limiting already impaired supplies
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
J&J says review of illness that led to pause of coronavirus vaccine trial could take days
October 12, 2020 9:08 PM EDTBy Reuters Staff
(Reuters) - Johnson & Johnson said on Tuesday it would take a few days at least to hear from a safety monitoring panel about its review of the company's late-stage COVID-19 vaccine trial after announcing that the large study had been paused due to an unexplained illness in one participant.
The pause comes around a month after AstraZeneca Plc also suspended trials of its experimental coronavirus vaccine - which uses a similar technology - due to a participant falling ill. That trial remains on pause.
U.S.-based J&J, whose vaccine effort... More
